Human papillomavirus (HPV) DNA in penile carcinomas in Argentina: Analysis of primary tumors and lymph nodes

Abstract Background Data about the genotype-specific human papillomavirus (HPV) prevalence in the Czech Republic is limited. We aimed to evaluate the prevalence and concordance of genotype-specific HPV infection detected in semen samples, penile swabs and cervical swabs from non-vaccinated heterosexual couples without HPV-associated disease. Methods Semen samples and penile swabs were collected from male partners and cervical swabs were collected from female partners of heterosexual couples treated for infertility (n = 195). Presence of HPV DNA in semen samples and cervical swabs was analyzed using the cobas® HPV Test and PapilloCheck®. Only the PapilloCheck® test was used to detect HPV in penile swabs. The genotype-specific prevalence and concordance of HPV infection not targeted by vaccine were evaluated using Fisher exact test. Results Both partners were infected with any HPV type in 13.8% (27/195) of couples and, of these couples, 55.6% (15/27) harbored at least one mutual genotype. High-risk HPV (hrHPV) genotypes were detected in 12.3% (24/195) of semen samples, 31.3% (61/195) of penile swabs, and 19.5% (38/195) of cervical swabs (P < 0.001). The most prevalent hrHPV genotype were HPV53 (2.56%; 5/195) in semen samples, HPV16 (6.67%, 13/195) in penile swabs and HPV39 (3.59%, 7/195) in cervical swabs. Low-risk (lrHPV) genotypes were detected in 5.13% (10/195) of semen samples, 15.9% (31/195) of penile swabs, and 4.10% (8/195) of cervical swabs (P < 0.001). Male sexual partners of HPV-positive women were more likely to be infected with at least one of the same HPV types than female sexual partners of HPV-positive men (34.9% vs. 17.9%, P = 0.055). Conclusions This study showed that the detection of HPV infection differ by anatomic site and gender. Regardless the anatomic site, high prevalence of HPV genital infection was found in both Czech men and women.

Download Full-text

Triage of human papillomavirus infected women by methylation analysis in first-void urine

Scientific Reports ◽

10.1038/s41598-021-87329-1 ◽

2021 ◽

Vol 11 (1) ◽

Author(s):

Severien Van Keer ◽

Annina P. van Splunter ◽

Jade Pattyn ◽

Annemie De Smet ◽

Sereina A. Herzog ◽

...

Keyword(s):

Human Papillomavirus ◽

Host Cell ◽

Intraepithelial Neoplasia ◽

Underlying Disease ◽

Hpv Infection ◽

Molecular Testing ◽

High Grade ◽

Methylation Analysis ◽

Hpv Dna ◽

Screening Attendance

AbstractHost cell DNA methylation analysis in urine provides promising triage markers for women diagnosed with a high-risk (HR) human papillomavirus (HPV) infection. In this study, we have investigated a panel of six host cell methylation markers (GHSR, SST, ZIC1, ASCL1, LHX8, ST6GALNAC5) in cervicovaginal secretions collected within the first part of the urine void (FVU) from a referral population. Cytology, histology, and HPV DNA genotyping results on paired FVU and cervical samples were available. Urinary median methylation levels from HR-HPV (n = 93) positive women were found to increase for all markers with severity of underlying disease. Significantly elevated levels were observed for GHSR and LHX8 in relation to high-grade cervical intraepithelial neoplasia (CIN2 +; n = 33), with area under de curve values of 0.80 (95% Confidence Interval (CI) 0.59–0.92) and 0.76 (95% CI 0.58–0.89), respectively. These findings are the first to support the assertion that methylation analysis of host cell genes is feasible in FVU and holds promise as molecular, triage strategy to discern low- from high-grade cervical disease in HR-HPV positive women. Molecular testing on FVU may serve to increase cervical cancer screening attendance in hard-to-reach populations whilst reducing loss to follow-up and await further optimization and validation studies.

Download Full-text

Pseudoepitheliomatous keratotic and micaceous balanitis: low-risk human papilloma virus detection in two further cases

International Journal of STD & AIDS ◽

10.1177/0956462420961947 ◽

2020 ◽

pp. 095646242096194

Author(s):

Marialuisa Corbeddu ◽

Luca Pilloni ◽

Roberta Satta ◽

Laura Atzori ◽

Franco Rongioletti

Keyword(s):

Human Papillomavirus ◽

Verrucous Carcinoma ◽

Virus Detection ◽

Low Risk ◽

Hpv Testing ◽

Papilloma Virus ◽

Hpv Dna ◽

Proliferative Markers ◽

Male Patients ◽

Papillomavirus Dna

We report two cases of histologically documented pseudoepitheliomatous keratotic and micaceous balanitis in middle-aged male patients, which showed positivity for low-risk serotype human papillomavirus DNA. To our knowledge, only one other case has been documented. Further immunohistochemical proliferative markers were performed and compared to literature findings in penile epithelial proliferations. Evolution to invasive verrucous carcinoma has been associated with absence of HPV DNA. Thus, if confirmed by further studies, HPV testing should be included in pseudoepitheliomatous keratotic and micaceous balanitis assessment to address prognosis, and management.

Download Full-text

Human Papillomavirus (HPV) DNA Triage of Women with Atypical Squamous Cells of Undetermined Significance with Amplicor HPV and Hybrid Capture 2 Assays for Detection of High-Grade Lesions of the Uterine Cervix

Journal of Clinical Microbiology ◽

10.1128/jcm.01063-10 ◽

2010 ◽

Vol 49 (1) ◽

pp. 48-53 ◽

Cited By ~ 10

Author(s):

S. Dufresne ◽

P. Sauthier ◽

M.-H. Mayrand ◽

P. Petignat ◽

D. Provencher ◽

...

Keyword(s):

Human Papillomavirus ◽

Uterine Cervix ◽

High Grade ◽

Hybrid Capture ◽

Hpv Dna ◽

Squamous Cells ◽

Hybrid Capture 2 ◽

Undetermined Significance

Download Full-text

BRAF/NRAS Mutation Frequencies Among Primary Tumors and Metastases in Patients With Melanoma

Journal of Clinical Oncology ◽

10.1200/jco.2011.41.2452 ◽

2012 ◽

Vol 30 (20) ◽

pp. 2522-2529 ◽

Cited By ~ 295

Author(s):

Maria Colombino ◽

Mariaelena Capone ◽

Amelia Lissia ◽

Antonio Cossu ◽

Corrado Rubino ◽

...

Keyword(s):

Lymph Nodes ◽

Primary Melanoma ◽

Similar Distribution ◽

Nras Mutation ◽

Tissue Samples ◽

Primary Tumors ◽

Paired Samples ◽

Automated Dna Sequencing ◽

Tumor Tissues ◽

Visceral Metastases

Purpose The prevalence of BRAF, NRAS, and p16CDKN2A mutations during melanoma progression remains inconclusive. We investigated the prevalence and distribution of mutations in these genes in different melanoma tissues. Patients and Methods In all, 291 tumor tissues from 132 patients with melanoma were screened. Paired samples of primary melanomas (n = 102) and synchronous or asynchronous metastases from the same patients (n = 165) were included. Tissue samples underwent mutation analysis (automated DNA sequencing). Secondary lesions included lymph nodes (n = 84), and skin (n = 36), visceral (n = 25), and brain (n = 44) sites. Results BRAF/NRAS mutations were identified in 58% of primary melanomas (43% BRAF; 15% NRAS); 62% in lymph nodes, 61% subcutaneous, 56% visceral, and 70% in brain sites. Mutations were observed in 63% of metastases (48% BRAF; 15% NRAS), a nonsignificant increase in mutation frequency after progression from primary melanoma. Of the paired samples, lymph nodes (93% consistency) and visceral metastases (96% consistency) presented a highly similar distribution of BRAF/NRAS mutations versus primary melanomas, with a significantly less consistent pattern in brain (80%) and skin metastases (75%). This suggests that independent subclones are generated in some patients. p16CDKN2A mutations were identified in 7% and 14% of primary melanomas and metastases, with a low consistency (31%) between secondary and primary tumor samples. Conclusion In the era of targeted therapies, assessment of the spectrum and distribution of alterations in molecular targets among patients with melanoma is needed. Our findings about the prevalence of BRAF/NRAS/p16CDKN2A mutations in paired tumor lesions from patients with melanoma may be useful in the management of this disease.

Download Full-text